All In Biotech

Drug Trial Radar · NCT05484622

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination With Pembrolizumab in Subjects With Recurrent or Progressive IDH-1 Mutant Glioma

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Actual

Start

Jan 20, 2023

Primary completion

Feb 12, 2026

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Aug 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.

Conditions

  • Astrocytoma
  • Oligodendroglioma

Interventions

  • VorasidenibDrug

    Administered orally as tablets.

  • PembrolizumabDrug

    Administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Lead-in Phase: Percentage of Participants With Dose-limiting Toxicities (DLTs)Time frame: First 21 days of dosing (Cycle 1) in safety lead-in phase
  2. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: approximately up to 19 months
  3. Percentage of Tumor-infiltrating Lymphocyte (TIL) Cells in Surgically Resected Tumors Following Treatment With Vorasidenib + Pembrolizumab Compared to Untreated Control TumorsTime frame: approximately 2 months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of California, Los Angeles (Site: 840113)

    Los Angeles, California

  • University of California, San Francisco (Site: 840149)

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • University of Miami (Site: 840129)

    Miami, Florida

  • Northwestern University (Site: 840123)

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital (Site: 840104)

    Boston, Massachusetts

  • Dana-Farber Cancer Institute (Site: 840139)

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Memorial Sloan Kettering Cancer Center (Site: 840117)

    New York, New York

  • Duke University (Site: 840110)

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Mayo Clinic Florida

    Cleveland, Ohio

  • University of Pennsylvania Health System

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center (Site: 840102)

    Houston, Texas

  • University of Utah, Huntsman Cancer Center

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.